Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals

Sobi no longer in acquisition talks

This article was originally published in Scrip

Executive Summary

Swedish Orphan Biovitrum (Sobi) says its board of directors has terminated discussions with its mystery potential buyer. It confirmed on 27 April that it had been approached regarding an acquisition. Likely suitors were touted as Biogen, Pfizer, Baxter or Novo Nordisk. Sobi said it would now continue to focus on preparations for the planned launch of Elocta (antihemophilic Factor (Recombinant), Fc Fusion Protein) and Alprolix (coagulation Factor IX (recombinant), Fc Fusion Protein) and on building value through its portfolio.

Table

View full table

Topics

Related Companies

Tags:
Deals
Latest Headlines

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

See All
UsernamePublicRestriction

Register

SC028928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By